Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.Elevidys treats Duchenne muscular dystrophy, a devastating disorder that ...

After a patch of ice sent Marc Durocher hurtling to the ground, and doctors at UMass Memorial Medical Center repaired the ...

Faculty in the Division of Biostatistics serve as principal investigators on several funded research projects, a sample of ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

Discover Iovance's Q4'24 revenue growth, Proleukin's impact on Amtagvi's future, and how it faces competition like Obsidian's ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

A MSU staff physician in an inappropriate relationship with a patient remained there for a year after concerns were raised.

What Happened? Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the ...

A Houston woman inspired by her mother's battle with Alzheimer's created the Cognitive Busy Box to help families connect with ...

Sarepta Therapeutics Inc.'s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute liver ...

Women at the University of Wisconsin conduct groundbreaking research every day to advance their fields of study and contribute to a better understanding of the world. UW ranks sixth in the nation for ...

Objectives This study was conducted to determine the predictors of sexual dysfunction and quality of life (QOL) in patients with type 2 diabetes (T2D). Sexual dysfunction is a long-term consequence of ...